These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7486803)

  • 1. Urinary iron excretion in patients with chronic obstructive airways disease (COAD).
    Gonzalez-Villaron L; Pérez-Arellano JL; de Castro S
    Ann Clin Biochem; 1995 Jul; 32 ( Pt 4)():417-8. PubMed ID: 7486803
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin, free erythrocyte protoporphyrin, and urinary iron excretion in patients with iron disorders.
    Walsh JR; Fredrickson M
    Am J Med Sci; 1977; 273(3):293-300. PubMed ID: 868919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary hemochromatosis. Diagnosis in siblings and children.
    Edwards CQ; Carroll M; Bray P; Cartwright GE
    N Engl J Med; 1977 Jul; 297(1):7-13. PubMed ID: 865566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-hour measurement of urinary iron excretion after deferoxine treatment: a rapid, simple method for study of iron excretion.
    Bonkovsky HL; Weber R; Aaron L
    Am J Gastroenterol; 1990 May; 85(5):554-7. PubMed ID: 2337058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum ferritin concentration as an evaluation of storage iron (author's transl)].
    Uchida T; Tanaka T; Umino M; Kimura H; Abe R; Matsuda S; Akizuki T; Kariyone S
    Rinsho Ketsueki; 1979 Nov; 20(11):1435-9. PubMed ID: 537165
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum ferritin, cobalt excretion and body iron status.
    Sorbie J; Valberg LS; Corbett WE; Ludwig J
    Can Med Assoc J; 1975 May; 112(10):1173-8. PubMed ID: 1125886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 12. [Findings in relation to serum and urinary iron in heterozygotic beta-thalassemia].
    Lodi G; Squarzoni G; Bariani MC; Fogli B; Masotti M; Musiari A; Bariani L
    G Clin Med; 1989 Apr; 70(4):263-6. PubMed ID: 2767366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison between serum ferritin and induced sideruria in the diagnosis of disorders of iron metabolism].
    Morini PL; Bianchi MA; Borsotti M
    Minerva Med; 1981 Oct; 72(40):2701-8. PubMed ID: 7290473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antianemic and potential anti-inflammatory activity of desferrioxamine: possible usefulness in rheumatoid arthritis.
    Giordano N; Sancasciani S; Borghi C; Fioravanti A; Marcolongo R
    Clin Exp Rheumatol; 1986; 4(1):25-9. PubMed ID: 3516495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary function abnormalities in thalassemia major and the role of iron overload.
    Factor JM; Pottipati SR; Rappoport I; Rosner IK; Lesser ML; Giardina PJ
    Am J Respir Crit Care Med; 1994 Jun; 149(6):1570-4. PubMed ID: 8004315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.